---
title: "Enhancing Adverse Drug Event Detection with Multimodal Dataset: Corpus Creation "
date: 2026-02-11
arxiv: "2405.15766"
category: "Annual Meeting of the Association for Computational Linguistics"
model: "google/gemma-3-4b-it:free"
---

# Enhancing Adverse Drug Event Detection with Multimodal Dataset: Corpus Creation and Model Development

## ğŸ“– ë…¼ë¬¸ ì •ë³´

| í•­ëª© | ë‚´ìš© |
|------|------|
| **ì €ì** | Pranab Sahoo, Ayush Kumar Singh, Sriparna Saha, Aman Chadha, S. Mondal |
| **ë°œí‘œì¼** | 2024-05-24 |
| **arXiv** | [2405.15766](https://arxiv.org/pdf/2405.15766) |
| **ì¹´í…Œê³ ë¦¬** | Annual Meeting of the Association for Computational Linguistics |

---

## ğŸ“ ì´ˆë¡ (Abstract)

The mining of adverse drug events (ADEs) is pivotal in pharmacovigilance, enhancing patient safety by identifying potential risks associated with medications, facilitating early detection of adverse events, and guiding regulatory decision-making. Traditional ADE detection methods are reliable but slow, not easily adaptable to large-scale operations, and offer limited information. With the exponential increase in data sources like social media content, biomedical literature, and Electronic Medical Records (EMR), extracting relevant ADE-related information from these unstructured texts is imperative. Previous ADE mining studies have focused on text-based methodologies, overlooking visual cues, limiting contextual comprehension, and hindering accurate interpretation. To address this gap, we present a MultiModal Adverse Drug Event (MMADE) detection dataset, merging ADE-related textual information with visual aids. Additionally, we introduce a framework that leverages the capabilities of LLMs and VLMs for ADE detection by generating detailed descriptions of medical images depicting ADEs, aiding healthcare professionals in visually identifying adverse events. Using our MMADE dataset, we showcase the significance of integrating visual cues from images to enhance overall performance. This approach holds promise for patient safety, ADE awareness, and healthcare accessibility, paving the way for further exploration in personalized healthcare.

---

## ğŸ” AI ë¶„ì„

## ë…¼ë¬¸ ìš”ì•½
ë³¸ ë…¼ë¬¸ì€ ì•½ë¬¼ ë¶€ì‘ìš©(ADE) íƒì§€ ë¶„ì•¼ì—ì„œ ê¸°ì¡´ì˜ í…ìŠ¤íŠ¸ ê¸°ë°˜ ë°©ì‹ì˜ í•œê³„ë¥¼ ê·¹ë³µí•˜ê¸° ìœ„í•´ ë©€í‹°ëª¨ë‹¬ ë°ì´í„°ì…‹(MMADE)ì„ êµ¬ì¶•í•˜ê³ , LLMê³¼ VLMì„ í™œìš©í•œ ADE íƒì§€ í”„ë ˆì„ì›Œí¬ë¥¼ ì œì‹œí•©ë‹ˆë‹¤. íŠ¹íˆ, ì˜ë£Œ ì´ë¯¸ì§€ì™€ ADE ê´€ë ¨ í…ìŠ¤íŠ¸ ì •ë³´ë¥¼ ê²°í•©í•˜ì—¬ ì˜ë£Œ ì „ë¬¸ê°€ê°€ ì‹œê°ì ìœ¼ë¡œ ë¶€ì‘ìš©ì„ ì‹ë³„í•˜ë„ë¡ ë•ëŠ”ë‹¤ëŠ” ì ì´ í•µì‹¬ì…ë‹ˆë‹¤. ì‹¤í—˜ ê²°ê³¼, ì‹œê°ì  ì •ë³´ í†µí•©ì€ ADE íƒì§€ ì„±ëŠ¥ì„ í–¥ìƒì‹œí‚¤ëŠ” ê²ƒì„ í™•ì¸í–ˆìœ¼ë©°, ì´ëŠ” í™˜ì ì•ˆì „, ë¶€ì‘ìš© ì¸ì‹, ì˜ë£Œ ì ‘ê·¼ì„± í–¥ìƒì— ê¸°ì—¬í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.

### ë°©ë²•ë¡  (Methodology)
ì œì•ˆí•˜ëŠ” ë°©ë²•ì€ í¬ê²Œ ë°ì´í„°ì…‹ êµ¬ì¶•ê³¼ ëª¨ë¸ ê°œë°œ ë‘ ë‹¨ê³„ë¡œ êµ¬ì„±ë©ë‹ˆë‹¤.

*   **MMADE ë°ì´í„°ì…‹ êµ¬ì¶•:** ADE ê´€ë ¨ í…ìŠ¤íŠ¸ ì •ë³´ì™€ í•¨ê»˜ ì˜ë£Œ ì´ë¯¸ì§€ë¥¼ ìˆ˜ì§‘í•˜ì—¬ MMADE ë°ì´í„°ì…‹ì„ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤. ë°ì´í„°ì…‹ êµ¬ì¶• ê³¼ì •ì€ êµ¬ì²´ì ìœ¼ë¡œ ëª…ì‹œë˜ì§€ ì•Šì•˜ì§€ë§Œ, ADE ê´€ë ¨ í…ìŠ¤íŠ¸ì™€ ì´ë¯¸ì§€ì˜ ì—°ê´€ì„±ì„ í™•ë³´í•˜ëŠ” ë° ì¤‘ì ì„ ë‘” ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤.
*   **ë©€í‹°ëª¨ë‹¬ ADE íƒì§€ í”„ë ˆì„ì›Œí¬:** LLMê³¼ VLMì„ í™œìš©í•˜ì—¬ ADE íƒì§€ë¥¼ ìˆ˜í–‰í•©ë‹ˆë‹¤. VLMì€ ì˜ë£Œ ì´ë¯¸ì§€ë¥¼ ì…ë ¥ë°›ì•„ ìƒì„¸í•œ ì„¤ëª…ì„ ìƒì„±í•˜ê³ , LLMì€ ìƒì„±ëœ ì„¤ëª…ì„ ê¸°ë°˜ìœ¼ë¡œ ADEë¥¼ íƒì§€í•©ë‹ˆë‹¤.  êµ¬ì²´ì ì¸ ëª¨ë¸ ì•„í‚¤í…ì²˜ëŠ” ëª…ì‹œë˜ì§€ ì•Šì•˜ì§€ë§Œ, LLMê³¼ VLMì˜ ìƒí˜¸ì‘ìš©ì„ í†µí•´ ì •ë³´ë¥¼ ìœµí•©í•˜ëŠ” ë°©ì‹ì´ ì‚¬ìš©ë˜ì—ˆì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤.  LLMê³¼ VLMì˜ êµ¬ì²´ì ì¸ ì¢…ë¥˜ëŠ” ì´ˆë¡ì— ëª…ì‹œë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.
*   **ê¸°ì¡´ ë°©ë²• ëŒ€ë¹„ ì°¨ë³„ì :** ê¸°ì¡´ì˜ í…ìŠ¤íŠ¸ ê¸°ë°˜ ADE íƒì§€ ë°©ì‹ì€ ì‹œê°ì  ì •ë³´ë¥¼ í™œìš©í•˜ì§€ ëª»í•œë‹¤ëŠ” í•œê³„ë¥¼ ê°€ì§€ê³  ìˆì—ˆìŠµë‹ˆë‹¤. ë³¸ ì—°êµ¬ëŠ” ì˜ë£Œ ì´ë¯¸ì§€ì™€ í…ìŠ¤íŠ¸ ì •ë³´ë¥¼ ê²°í•©í•˜ì—¬ ADE íƒì§€ ì„±ëŠ¥ì„ í–¥ìƒì‹œí‚¤ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤.

### ì‹¤í—˜ ë° ê²°ê³¼ (Experiments & Results)
ì´ˆë¡ì— êµ¬ì²´ì  ìˆ˜ì¹˜ ë¯¸ê¸°ì¬, ì›ë¬¸ í™•ì¸ í•„ìš”.  MMADE ë°ì´í„°ì…‹ì„ ì‚¬ìš©í•˜ì—¬ ì‹¤í—˜ì„ ìˆ˜í–‰í–ˆìœ¼ë©°,  êµ¬ì²´ì ì¸ ë²¤ì¹˜ë§ˆí¬ ë°ì´í„°ì…‹ì€ ëª…ì‹œë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.  ë¹„êµ ëŒ€ìƒ ëª¨ë¸(baseline)ì— ëŒ€í•œ ì •ë³´ë„ ì´ˆë¡ì— ëª…ì‹œë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.  ê·¸ëŸ¬ë‚˜, ì‹œê°ì  ì •ë³´ í†µí•©ì´ ADE íƒì§€ ì„±ëŠ¥ì„ í–¥ìƒì‹œí‚¨ë‹¤ëŠ” ê²°ê³¼ë¥¼ ì œì‹œí•˜ê³  ìˆìŠµë‹ˆë‹¤.  SOTA ë‹¬ì„± ì—¬ë¶€ ë° ê°œì„  í­ì— ëŒ€í•œ ì •ë³´ë„ ì´ˆë¡ì— ëª…ì‹œë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.

### ìƒˆë¡œìš´ ì  (Novelty)
ë³¸ ë…¼ë¬¸ì˜ í•µì‹¬ì ì¸ ìƒˆë¡œìš´ ì ì€ ì˜ë£Œ ì´ë¯¸ì§€ì™€ í…ìŠ¤íŠ¸ ì •ë³´ë¥¼ ê²°í•©í•˜ì—¬ ADE íƒì§€ ì„±ëŠ¥ì„ í–¥ìƒì‹œí‚¤ëŠ” ë©€í‹°ëª¨ë‹¬ ì ‘ê·¼ ë°©ì‹ì…ë‹ˆë‹¤. íŠ¹íˆ, VLMì„ í™œìš©í•˜ì—¬ ì˜ë£Œ ì´ë¯¸ì§€ë¥¼ ì„¤ëª…í•˜ê³ , LLMì„ í™œìš©í•˜ì—¬ ADEë¥¼ íƒì§€í•˜ëŠ” í”„ë ˆì„ì›Œí¬ëŠ” ê¸°ì¡´ì˜ í…ìŠ¤íŠ¸ ê¸°ë°˜ ë°©ì‹ê³¼ëŠ” ì°¨ë³„í™”ë©ë‹ˆë‹¤.  ë˜í•œ, ADE ê´€ë ¨ ì‹œê°ì  ì •ë³´ë¥¼ í™œìš©í•˜ì—¬ ì˜ë£Œ ì „ë¬¸ê°€ì˜ ì˜ì‚¬ ê²°ì •ì„ ì§€ì›í•˜ëŠ” ê²ƒì€ ì¤‘ìš”í•œ ê¸°ì—¬ì…ë‹ˆë‹¤.

### ê°•ì  (Strengths)
1.  **ë©€í‹°ëª¨ë‹¬ ë°ì´í„°ì…‹ êµ¬ì¶•:** ADE íƒì§€ ë¶„ì•¼ì—ì„œ ì‹œê°ì  ì •ë³´ì˜ ì¤‘ìš”ì„±ì„ ê°•ì¡°í•˜ê³ , ì´ë¥¼ ë°˜ì˜í•œ ë©€í‹°ëª¨ë‹¬ ë°ì´í„°ì…‹ì„ êµ¬ì¶•í–ˆìŠµë‹ˆë‹¤.
2.  **LLMê³¼ VLM í™œìš©:** LLMê³¼ VLMì„ ê²°í•©í•˜ì—¬ ADE íƒì§€ ì„±ëŠ¥ì„ í–¥ìƒì‹œí‚¤ëŠ” ìƒˆë¡œìš´ í”„ë ˆì„ì›Œí¬ë¥¼ ì œì‹œí–ˆìŠµë‹ˆë‹¤.
3.  **ì˜ë£Œ ì „ë¬¸ê°€ ì§€ì›:** ì˜ë£Œ ì´ë¯¸ì§€ë¥¼ ì„¤ëª…í•˜ê³  ADEë¥¼ íƒì§€í•˜ëŠ” ë°©ì‹ìœ¼ë¡œ ì˜ë£Œ ì „ë¬¸ê°€ì˜ ì˜ì‚¬ ê²°ì •ì„ ì§€ì›í•©ë‹ˆë‹¤.

### ì•½ì /í•œê³„ì  (Limitations)
1.  **ë°ì´í„°ì…‹ ê·œëª¨ ë° ë‹¤ì–‘ì„±:** MMADE ë°ì´í„°ì…‹ì˜ ê·œëª¨ì™€ ë‹¤ì–‘ì„±ì— ëŒ€í•œ ì •ë³´ê°€ ë¶€ì¡±í•©ë‹ˆë‹¤.
2.  **ëª¨ë¸ ì•„í‚¤í…ì²˜:** LLMê³¼ VLMì˜ êµ¬ì²´ì ì¸ ëª¨ë¸ ì•„í‚¤í…ì²˜ ë° í•™ìŠµ ë°©ë²•ì´ ëª…ì‹œë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤.
3.  **ë²¤ì¹˜ë§ˆí¬ ë° ë¹„êµ ëŒ€ìƒ ëª¨ë¸:**  ì–´ë–¤ ë²¤ì¹˜ë§ˆí¬ ë°ì´í„°ì…‹ì„ ì‚¬ìš©í–ˆê³ , ì–´ë–¤ ëª¨ë¸ê³¼ ë¹„êµí–ˆëŠ”ì§€ì— ëŒ€í•œ ì •ë³´ê°€ ë¶€ì¡±í•©ë‹ˆë‹¤.

### ë‚´ ì—°êµ¬ì™€ì˜ ì—°ê´€ì„±
ë³¸ ë…¼ë¬¸ì˜ ë©€í‹°ëª¨ë‹¬ ì ‘ê·¼ ë°©ì‹ì€ ì‚¬ìš©ìì˜ ì—°êµ¬ ì£¼ì œì¸ MLLM merging, Korean MLLM, vision-text alignment, document/chart/OCR/table VQA ì—°êµ¬ì™€ ë°€ì ‘í•˜ê²Œ ê´€ë ¨ë©ë‹ˆë‹¤. íŠ¹íˆ, VLMì„ í™œìš©í•˜ì—¬ ì´ë¯¸ì§€ì™€ í…ìŠ¤íŠ¸ë¥¼ ì •ë ¬í•˜ëŠ” ë°©ì‹ì€ ë¬¸ì„œ/ì°¨íŠ¸/OCR/í…Œì´ë¸” VQA ì—°êµ¬ì— ì ìš©ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ, í•œêµ­ì–´ MLLM ê°œë°œ ì‹œ, í•œêµ­ì–´ í…ìŠ¤íŠ¸ì™€ ì´ë¯¸ì§€ ì •ë³´ë¥¼ ê²°í•©í•˜ì—¬ ì„±ëŠ¥ì„ í–¥ìƒì‹œí‚¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. MLLM merging ì—°êµ¬ì—ì„œëŠ” ë‹¤ì–‘í•œ ëª¨ë¸ì„ ê²°í•©í•˜ì—¬ ì„±ëŠ¥ì„ ê·¹ëŒ€í™”í•˜ëŠ” ë°©ì•ˆì„ ëª¨ìƒ‰í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.

### ì—°êµ¬ ì•„ì´ë””ì–´ ì œì•ˆ
1.  **MMADE ë°ì´í„°ì…‹ í™•ì¥:** MMADE ë°ì´í„°ì…‹ì˜ ê·œëª¨ì™€ ë‹¤ì–‘ì„±ì„ í™•ì¥í•˜ì—¬, ë‹¤ì–‘í•œ ìœ í˜•ì˜ ADEì™€ ì˜ë£Œ ì´ë¯¸ì§€ë¥¼ í¬í•¨í•˜ë„ë¡ í•©ë‹ˆë‹¤.
2.  **Korean MMADE ë°ì´í„°ì…‹ êµ¬ì¶•:** í•œêµ­ì–´ ì˜ë£Œ ì´ë¯¸ì§€ì™€ í…ìŠ¤íŠ¸ ì •ë³´ë¥¼ í™œìš©í•˜ì—¬ Korean MMADE ë°ì´í„°ì…‹ì„ êµ¬ì¶•í•˜ê³ , í•œêµ­ì–´ MLLM ì„±ëŠ¥ í–¥ìƒì— í™œìš©í•©ë‹ˆë‹¤.
3.  **DocVQA/ChartQA/TableVQAì— ì ìš©:** ì œì•ˆí•˜ëŠ” ë©€í‹°ëª¨ë‹¬ í”„ë ˆì„ì›Œí¬ë¥¼ DocVQA, ChartQA, TableVQAì™€ ê°™ì€ VQA ë°ì´í„°ì…‹ì— ì ìš©í•˜ì—¬, ì‹œê°ì  ì •ë³´ë¥¼ í™œìš©í•œ ì§ˆë¬¸ ë‹µë³€ ì„±ëŠ¥ì„ í–¥ìƒì‹œí‚µë‹ˆë‹¤.

### í•µì‹¬ í‚¤ì›Œë“œ
Multimodal Large Language Models (MLLM), Adverse Drug Event (ADE) Detection, Vision-Language Alignment, Medical Imaging, Document VQA, Chart VQA, OCR Multimodal, Table VQA, Multimodal LLM, Visual Instruction Tuning

---

> ğŸ¤– ì´ ê¸€ì€ AI ì—°êµ¬ ì–´ì‹œìŠ¤í„´íŠ¸ì— ì˜í•´ ìë™ ìƒì„±ë˜ì—ˆìŠµë‹ˆë‹¤.
> ë¶„ì„ ëª¨ë¸: google/gemma-3-4b-it:free
